Most Recent Posts
We at PhRMA have been pretty vocal this year in support of important legislation that helps improve the care that children receive across the country, both he
If you've read some of my previous posts about PDUFA but found yourself resorting to Google to figure out what in the heck I'm talking about, you'll want to take a few minutes to watch a video that we made for We Work For Health, so that biopharmaceutical company employees have a chance to learn about it, too.
After all, as the video says, it's important legislation!
Today is World Asthma Day, an effort to raise awareness about asthma and improve asthma care for patients. Asthma is a chronic disease that affects people all over the world. It imposes a growing burden on society, with prevalence on the rise and an annual economic cost of $19.7 billion.
We talked with Dave Allen, Senior Vice President of the Respiratory Therapy Area at GlaxoSmithKline on why asthma education and care is so important.
Why is asthma awareness/education important?
With today being World Asthma Day, PhRMA joins with public health officials, health organizations, and patient groups around the world to emphasize that you can control your asthma, the theme for 2012.
Wow! That was what I said when I read the Reuters article about America's growing waistlines. It is truly troubling that incidents of extreme or "morbid" obesity has risen sixfold in the U.S. since 1960 and that medical spending due to obesity is now exceeding costs associated with smoking.
As I put final touches on my weekend plans, I wanted to flag Saturday for folks - it's the Drug Enforcement Administration (DEA) National Take Back Day.
In a recent op-ed in The Boston Globe, Merck's Chief Medical Officer Mike Rosenblatt and Dr. Harris Berman, Dean of Tufts Medical School, commented on the pressing need to fix a fundamental problem in healthcare today: getting patients to take their medications.
There has been a lot of talk lately in the run-up to the election about the economy and what types of policies are needed to improve the outlook of our nation. I've found that in almost every election year, we hear a whole host of proposals offered that both Republicans and Democrats claim can provide some sort of silver bullet to our economic woes. But we all know there is no silver bullet, especially if we remain so divided as a nation on what type of solutions are needed to provide a more economically secure future.
How many of you have gone to an Internet pharmacy site to purchase medicines and found that the prices were artificially low? While everybody likes a good deal, including me, there have been several warnings to consumers by the Food and Drug Administration about rogue online pharmacy sites that offer deals too good to be true.
This morning, my colleague Sharon Brigner alerted me to an article in the Wall Street Journal (subscription required) about some efforts by patient advocacy groups to help increase patient awareness of clinical trials.
When most of us think of vaccines, we probably think of the vaccinations we received as children, the ones that left our arms sore, even days later. Vaccines have been used to successfully prevent diseases such as smallpox, measles, polio and other infectious diseases, for many years. But vaccines are not only for preventing infectious diseases;newer vaccines are providing protections against a wide array of other diseases, including cancer prevention.
We can - and do - talk about the Alzheimer's disease: what it is and how you detect it. We can talk about what it means for patients and our economy if we don't find new treatments and a way to delay its onset.
Earlier today I came across the news that the venerable Levon Helm, singer and drummer for The Band and multi-Grammy award winner as a solo artist, is in the very late stages of his battle with cancer. I don't know about all of you, but I can't count how many times I've watched/listened to "The Last Waltz," mesmerized by the artistry and energy that Helm and his Band-mates brought to the stage.
Helm is an amazing talent, even after he lost and then regained his voice in earlier bouts with throat cancer.
Today has been a big day for reauthorization of the Prescription Drug User Fee Act - which, as a reminder, is legislation that must pass by the end of September at the latest.
We're viewing a new survey from the National Coalition on Healthcare (NCHC) with a healthy dose of skepticism. Not only do we not agree with the results, but we feel strongly that when discussing copay coupons, it's important to understand why they are necessary.
I recently worked with the American Cancer Society and some local biotech executives on the launch of a new report - Research in Your Backyard: Pharmaceutical Clinical Trials in Oregon. We all agreed that this report was a good start, but that more needed to be done to solve the largest challenge facing clinical trials today: educating patients about the importance of participation.
This is a guest post from John C. Lechleiter, PhD, who is Chairman, President and CEO of Eli Lilly and Company. Starting today, Mr. Lechleiter is also the Chairman of the Board of Directors of PhRMA.